Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
C$0.00
C$11.77
C$26.00
C$2.15BN/A229,895 shs4.61 million shs
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
$5.28
-4.2%
$6.14
$3.96
$9.85
$1.95B0.432.70 million shs2.31 million shs
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$31.32
$24.33M0.4123,217 shs237,144 shs
Tervita Co. stock logo
TEV
Tervita
C$0.00
C$1.69
C$6.46
C$672.00MN/A79,738 shs15,893 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
+1.66%+5.87%-15.19%-26.32%-38.13%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%+3.30%+6.61%-41.32%
Tervita Co. stock logo
TEV
Tervita
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
4.1992 of 5 stars
2.93.00.04.02.61.71.9
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
3.8616 of 5 stars
3.05.00.04.22.70.80.0
Tervita Co. stock logo
TEV
Tervita
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
0.00
N/AN/AN/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
1.86
Reduce$7.1735.73% Upside
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
2.00
Hold$83.52∞ Upside
Tervita Co. stock logo
TEV
Tervita
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TEV, AUP, BHC, and CARA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/7/2025
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform$9.00 ➝ $8.50
2/6/2025
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$12.00 ➝ $8.00
1/30/2025
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$11.00 ➝ $10.00
(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
C$57.59M0.00N/A6.75C$2.59 per share0.00
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
$9.63B0.20$5.62 per share0.94($0.89) per share-5.93
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
Tervita Co. stock logo
TEV
Tervita
C$1.36B0.00N/A29.62C$1.58 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A-C$1.48N/AN/AN/AN/AN/AN/AN/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
-$46M-$0.12N/A1.130.37-0.48%-577.82%5.24%4/30/2025 (Estimated)
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%5/12/2025 (Estimated)
Tervita Co. stock logo
TEV
Tervita
N/A-C$0.01N/AN/AN/AN/AN/AN/AN/A

Latest TEV, AUP, BHC, and CARA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2025Q1 2025
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
$1.46$0.59-$0.87-$0.16$2.29 billionN/A
2/19/2025Q4 2024
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
$1.65$1.21-$0.44$0.25$2.51 billion$2.56 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
N/AN/AN/AN/AN/A
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
Tervita Co. stock logo
TEV
Tervita
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
2.69
11.93
11.02
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
N/A
0.86
0.62
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
Tervita Co. stock logo
TEV
Tervita
440.44
1.00
0.86

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
78.65%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
Tervita Co. stock logo
TEV
Tervita
N/A

Insider Ownership

CompanyInsider Ownership
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
N/A
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
8.12%
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
3.10%
Tervita Co. stock logo
TEV
Tervita
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUP
Aurinia Pharmaceuticals
300128.40 millionN/ANot Optionable
Bausch Health Companies Inc. stock logo
BHC
Bausch Health Companies
19,900369.51 million338.06 millionOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
Tervita Co. stock logo
TEV
Tervita
36,800115.66 millionN/ANot Optionable

Recent News About These Companies

Tev Monnin
Understanding Risk for Venous Thromboembolism (VTE)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals TSE:AUP

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Bausch Health Companies stock logo

Bausch Health Companies NYSE:BHC

$5.28 -0.23 (-4.17%)
As of 03:59 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Tervita stock logo

Tervita TSE:TEV

Tervita Corporation operates as an environmentally focused waste service provider in Canada and the United States. It operates through two segments, Energy Services and Industrial Services. The Energy Services segment treats, recovers, and disposes fluids; provides oil terminalling and energy marketing services; processes and disposes solid materials; disposes oilfield-generated waste; offers onsite services using centrifugation or other processes for heavy oil producers involved in mining and in situ production; and purchases and sells oil volumes with treatment, recovery, terminalling, and disposal services. The Industrial Services segment provides site remediation, facility decommissioning, water treatment, sludge and slurry management, bio-remediation and technologies, technical, environmental liability management, emergency response, and rail services, as well as hazardous and non-hazardous waste management, and disposal services. This segment also offers recycling services that include purchase and processing of ferrous and non-ferrous metals recovered from demolition sites and other locations. As of December 31, 2020, the company operated 103 active waste processing, disposal, and industrial facilities, including 44 treatment, recovery, and disposal facilities; eight stand-alone disposal wells; three cavern disposal facilities; eight onsite facilities; 22 engineered landfills; three transfer stations; one naturally occurring radioactive material facility; nine bioremediation facilities; and five metals recycling facilities. It serves oil and gas industry, and industrial and natural resource sectors. The company was formerly known as CCS Corporation and changed its name to Tervita Corporation in March 2012. Tervita Corporation was founded in 1979 and is headquartered in Calgary, Canada.